Since our inception as a “research and innovation” organization in 2012, we have been on a relentless pursuit to overcome gut-mediated diseases. As a biotech company, we aspire to design a future where patients suffering from chronic kidney disease (CKD) and liver cirrhosis can look forward to healthier tomorrows.
At the intersection of biotech innovation and technology, our therapeutic approach revolves around synbiotics, enzobiotics, and enzotein research. This forms the cornerstone of future medical research, fostering a highly personalized healthcare paradigm that takes into account each individual’s unique hidden metabolic signature. With a dedicated vision to uncover these concealed metabolic markers within the intricate network of the gut’s 100 trillion microbiota, we recognize the profound impact of microbiota dysbiosis on quality of life and its role in various ailments. Our unwavering commitment drives us to pioneer evidence-based research, aimed at delivering tailored therapeutic solutions.
Over the last decade, we have been at the forefront of investigating the Gut-Kidney Axis, Gut-Brain Axis, and the Gut-Liver Axis, recognizing the pivotal role these play in understanding and managing gut-mediated diseases.
Derived from the Greek Word “probiotic,” meaning “for life,” probiotics are live microorganisms that benefit health when consumed in the right amounts. Prebiotics, on the other hand, support probiotic bacteria growth in the body. Synbiotics, a combination of both, play a therapeutic role in maintaining a healthy gastrointestinal tract. Notably, they reduce inflammatory markers like HSCRP, IL-6, and TNF-α . This makes them effective in managing conditions like uremic pruritus and Kyrle’s disease (KD), particularly in the context of chronic kidney disease (CKD) and uraemia. Synbiotics thus significantly enhance well-being through their profound gut health impact.
A special combination of synbiotics and proteolytic enzymes can effectively slow down the advancement of Chronic Kidney Disease (CKD) to higher stages. These compounds work by transforming the gut from a dysbiotic state to a healthy state, leading to a significant decrease in the generation of protein-bound uremic toxins PCS and IS. These toxins are biomarkers connected to a decline in kidney function. PCS (p-Cresol sulfate) and IS (Indoxyl sulfate) contribute to renal tubular damage by triggering free-radical production, upregulating nuclear factor (NF)-kB and PAI-1, and enhancing the expression of TGF Beta 1. Indoxyl sulfate also helps prevent Aortic Calcification and Vascular Stiffness. Enzobiotics not only significantly improve the quality of life but also show promise in preventing the progression of CKD to Cardiovascular Disease (CVD) by reducing PCS and IS.
Enzotein, a unique blend of proteolytic enzymes and low-dose protein supplements, effectively tackles protein energy malnutrition in economically disadvantaged end-stage renal disease (ESRD) patients. By enhancing protein breakdown and assimilation, Enzotein matches the nutritional and anti-inflammatory benefits of high-dose protein intake. This innovative combination excels at facilitating the efficient breakdown, assimilation, and absorption of proteins with an impressive PDCAAS value >1. This innovative approach can serve as a viable, cost-effective solution in resource-limited settings, promising to alleviate protein energy malnutrition and accelerate recovery, potentially shortening the healing process by 18 months for ESRD patients undergoing hemodialysis.